卵巢癌治疗中卡铂剂量:一项NRG肿瘤学组研究
该回顾性研究基于GOG182试验中3830例晚期卵巢癌患者,评估用NCCN指南估算肾功能对卡铂剂量的影响,并探索更准确估算较低肌酐清除率(CrCl)的不良反应。结果显示不同公式影响卡铂剂量,Jelliffe估算的CrCl<60 mL/min不能准确预测不良事件。
要点
- 不同肾功能估算公式导致卡铂剂量变化:Cockcroft-Gault、Cockcroft-Gault联合NCCN修改、MDRD相比Jelliffe分别有16%、32%、5.2%患者剂量降低>10%,41%、9.6%、12%患者剂量增加>10%。
- Jelliffe估算的CrCl<60 mL/min不能准确预测≥3级不良事件(AUC 0.52-0.64)。
- 数据不支持将CrCl<60 mL/min作为临床试验排除标准的最低阈值。
核心结论
- 估算CrCl的公式影响卡铂剂量;Jelliffe估算的CrCl<60 mL/min不能准确预测不良事件,数据不支持将CrCl<60 mL/min作为临床试验排除标准。
研究设计与样本
- 回顾性研究,纳入GOG182试验(NCT00011986)中4312例患者中的3830例,该试验为晚期卵巢癌铂类化疗的III期试验。
主要发现
- AUC统计量(范围0.52-0.64)显示log(CrClJelliffe)不能良好预测≥3级不良事件(贫血、血小板减少、发热性中性粒细胞减少、听觉、肾脏、代谢、神经系统)。
- 3830例患者中628例(16%)CrCl<60 mL/min。
- 不良事件阳性预测值范围为1.8%-15%。
- 使用Cockcroft-Gault、Cockcroft-Gault联合NCCN修改、MDRD(替代Jelliffe)公式估算肾功能,分别导致16%、32%、5.2%的患者卡铂剂量降低>10%,分别导致41%、9.6%、12%的患者卡铂剂量增加>10%。
临床怎么用
- 数据不支持将CrCl<60 mL/min作为临床试验排除标准的最低阈值,并支持美国国家癌症研究所扩大研究入选标准的倡议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation of lower creatinine clearance (CrCl). METHODS: Retrospective data were obtained for 3830 of 4312 patients treated on GOG182 (NCT00011986)-a phase III trial of platinum-based chemotherapy for advanced-stage ovarian cancer. Carboplatin dose per patient on GOG182 was determined using the Jelliffe formula. We recalculated CrCl to determine dosing using Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (with/without NCCN recommended modifications) formulas. Associations between baseline CrCl and toxicity were described using the area under the receiver operating characteristic curve (AUC). Sensitivity and positive predictive values described the model's ability to discriminate between subjects with/without the adverse event. RESULTS: AUC statistics (range, 0.52-0.64) showed log(CrClJelliffe) was not a good predictor of grade ≥3 adverse events (anemia, thrombocytopenia, febrile neutropenia, auditory, renal, metabolic, neurologic). Of 3830 patients, 628 (16%) had CrCl <60 mL/min. Positive predictive values for adverse events ranged from 1.8%-15%. Using the Cockcroft-Gault, Cockcroft-Gault with NCCN modifications, and MDRD (instead of Jelliffe) formulas to estimate renal function resulted in a >10% decrease in carboplatin dosing in 16%, 32%, and 5.2% of patients, respectively, and a >10% increase in carboplatin dosing in 41%, 9.6% and 12% of patients, respectively. CONCLUSION: The formula used to estimate CrCl affects carboplatin dosing. Estimated CrCl <60 mL/min (by Jelliffe) did not accurately predict adverse events. Efforts continue to better predict renal function. Endorsing National Cancer Institute initiatives to broaden study eligibility, our data do not support a minimum threshold CrCl <60 mL/min as an exclusion criterion from clinical trials.
引用
- Praiss AM, Miller A, Smith J, et al. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. Gynecol Oncol. 2023. PMID: 37229879. doi:10.1016/j.ygyno.2023.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。